Vitamin K Deficiency

DUBLIN, Aug. 11, 2022 /PRNewswire/ -- The "Global Hematology Partnering 2010-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The Global Hematology Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 650 hematology deals signed since 2010. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive Hematology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hematology deals. The report presents financial deal terms values for Hematology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. The report includes deals for the following indications: Agranulocytosis, Anemia, Haemolytic, Iron deficiency, Blood substitute, Disseminated intravascular coagulation (DIC), Hemophilia, Immune thrombocytopenic purpura, Neutropenia, Polycythemia, Thalassemia, Thrombocytopenia, Vitamin K Deficiency, Von-Willebrand disease, plus other hematological indications. The initial chapters of this report provide an orientation of Hematology dealmaking trends. Chapter 1 provides an introduction to the report. Chapter 2 provides an overview of the trends in Hematology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication. Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates. Chapter 4 provides a review of the leading Hematology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Hematology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 5 provides comprehensive access to Hematology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive directory of all Hematology partnering deals by specific Hematology target announced since 2010. The chapter is organized by specific Hematology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided with each report of all Hematology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Hematology technologies and products. Report scope Global Hematology Partnering 2010 to 2022 includes: Trends in Hematology dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to hundreds of Hematology deal contract documents Comprehensive access to over 650 Hematology deal records The leading Hematology deals by value since 2010 Most active Hematology dealmakers since 2010 In Global Hematology Partnering 2010 to 2022, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are the sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Hematology dealmaking 2.1. Introduction 2.2. Hematology partnering over the years 2.3. Hematology partnering by deal type 2.4. Hematology partnering by industry sector 2.5. Hematology partnering by stage of development 2.6. Hematology partnering by technology type 2.7. Hematology partnering by therapeutic indication Chapter 3 - Financial deal terms for Hematology partnering 3.1. Introduction 3.2. Disclosed financials terms for Hematology partnering 3.3. Hematology partnering headline values 3.4. Hematology deal upfront payments 3.5. Hematology deal milestone payments 3.6. Hematology royalty rates Chapter 4 - Leading Hematology deals and dealmakers 4.1. Introduction 4.2. Most active in Hematology partnering 4.3. List of most active dealmakers in Hematology 4.4. Top Hematology deals by value Chapter 5 - Hematology contract document directory 5.1. Introduction 5.2. Hematology partnering deals where contract document available Chapter 6 - Hematology dealmaking by therapeutic target 6.1. Introduction 6.2. Deals by Hematology therapeutic target Appendices Appendix 1 - Directory of Hematology deals by company A-Z 2010 to 2022 Appendix 2 - Directory of Hematology deals by deal type 2010 to 2022 Appendix 3 - Directory of Hematology deals by stage of development 2010 to 2022 Appendix 4 - Directory of Hematology deals by technology type 2010 to 2022 For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Dublin, June 17, 2021 (GLOBE NEWSWIRE) -- The "Global Hematology Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The Global Hematology Partnering 2010-2021 report provides comprehensive access to available deals and contract documents for over 550 hematology deals. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.The report takes readers through the comprehensive Hematology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hematology deals.The report presents financial deal terms values for Hematology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.In addition, a comprehensive appendix is provided with each report of all Hematology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report includes deals for the following indications: Agranulocytosis, v, Haemolytic, Iron deficiency, Blood substitute, Disseminated intravascular coagulation (DIC), Hemophilia, Immune thrombocytopenic purpura, Neutropenia, Polycythemia, Thalassemia, Thrombocytopenia, Vitamin K Deficiency, Von-Willebrand disease, plus other hematological indications. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Hematology technologies and products.Report scopeGlobal Hematology Partnering 2010 to 2021 includes: Available deals and contracts are listed by: Analyzing actual contract agreements allows assessment of the following: Key Topics Covered: Executive SummaryChapter 1 - IntroductionChapter 2 - Trends in Hematology dealmaking2.1. Introduction2.2. Hematology partnering over the years 2.3. Hematology partnering by deal type2.4. Hematology partnering by industry sector2.5. Hematology partnering by stage of development2.6. Hematology partnering by technology type2.7. Hematology partnering by therapeutic indicationChapter 3 -Financial deal terms for Hematology partnering3.1. Introduction3.2. Disclosed financials terms for Hematology partnering3.3. Hematology partnering headline values3.4. Hematology deal upfront payments3.5. Hematology deal milestone payments3.6. Hematology royalty ratesChapter 4 - Leading Hematology deals and dealmakers4.1. Introduction4.2. Most active in Hematology partnering4.3. List of most active dealmakers in Hematology 4.4. Top Hematology deals by valueChapter 5 - Hematology contract document directory5.1. Introduction5.2. Hematology partnering deals where contract document availableChapter 6 - Hematology dealmaking by therapeutic target6.1. Introduction6.2. Deals by Hematology therapeutic targetAppendices Appendix 1 - Directory of Hematology deals by company A-Z 2010 to 2021Appendix 2 - Directory of Hematology deals by deal type 2010 to 2021Appendix 3 - Directory of Hematology deals by stage of development 2010 to 2021Appendix 4 - Directory of Hematology deals by technology type 2010 to 2021 For more information about this report visit

Dr. Reddy's Laboratories, an India-based pharmaceutical company, is recalling four lots of its phytonadione injections after receiving complaints the containers were breaking and shattering upon opening. Phytonadione injections are used to treat vitamin K deficiency, which can cause things such as jaundice, ulcerative colitis and celiac disease. The company received complaints that the glass bottles containing the liquid drug were shattering upon opening, causing cuts. Dr. Reddy's said flying glass could injure eyes, skin or other body parts if the recalled lots are used. The company specified the recalled drugs were only distributed within the U.S. Read the full news release here.